- Home
- CADL vs MXCT Comparison
CADL vs MXCT Comparison
Compare CADL & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- MXCT
- Stock Information
- Founded
- CADL 1999
- MXCT 1999
- Country
- CADL United States
- MXCT United States
- Employees
- CADL N/A
- MXCT N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CADL Health Care
- MXCT Health Care
- Exchange
- CADL Nasdaq
- MXCT Nasdaq
- Market Cap
- CADL 234.8M
- MXCT 239.2M
- IPO Year
- CADL 2021
- MXCT 2021
- Fundamental
- Price
- CADL $5.45
- MXCT $2.38
- Analyst Decision
- CADL Strong Buy
- MXCT Strong Buy
- Analyst Count
- CADL 4
- MXCT 1
- Target Price
- CADL $21.00
- MXCT $9.00
- AVG Volume (30 Days)
- CADL 991.5K
- MXCT 1.3M
- Earning Date
- CADL 05-13-2025
- MXCT 05-07-2025
- Dividend Yield
- CADL N/A
- MXCT N/A
- EPS Growth
- CADL N/A
- MXCT N/A
- EPS
- CADL N/A
- MXCT N/A
- Revenue
- CADL N/A
- MXCT $37,675,000.00
- Revenue This Year
- CADL N/A
- MXCT $8.82
- Revenue Next Year
- CADL N/A
- MXCT $21.12
- P/E Ratio
- CADL N/A
- MXCT N/A
- Revenue Growth
- CADL N/A
- MXCT N/A
- 52 Week Low
- CADL $3.79
- MXCT $2.10
- 52 Week High
- CADL $14.60
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- CADL 50.27
- MXCT 47.12
- Support Level
- CADL $5.18
- MXCT $2.18
- Resistance Level
- CADL $6.29
- MXCT $2.40
- Average True Range (ATR)
- CADL 0.41
- MXCT 0.13
- MACD
- CADL 0.08
- MXCT 0.02
- Stochastic Oscillator
- CADL 42.89
- MXCT 75.88
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.